Angiogenesis Inhibitors in NSCLC
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with a...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/18/10/2021 |
id |
doaj-26be4d44f1404d4eb3e1f6107436e2ba |
---|---|
record_format |
Article |
spelling |
doaj-26be4d44f1404d4eb3e1f6107436e2ba2020-11-24T21:38:52ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-09-011810202110.3390/ijms18102021ijms18102021Angiogenesis Inhibitors in NSCLCAnna Manzo0Agnese Montanino1Guido Carillio2Raffaele Costanzo3Claudia Sandomenico4Nicola Normanno5Maria Carmela Piccirillo6Gennaro Daniele7Francesco Perrone8Gaetano Rocco9Alessandro Morabito10Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyDepartment of Oncology and Hematology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyCellular Biology and Biotherapy, Research Department, Istituto Nazionale Tumori “Fondazione G.Pascale”—IRCCS, Napoli 80131, ItalyClinical Trials Unit, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyClinical Trials Unit, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyClinical Trials Unit, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyThoracic Surgery, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, ItalyAngiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy; however, it was limited to patients with non-squamous histology and first-line setting. Approval was based on the results of two phase III trials (ECOG4599 and AVAIL) that demonstrated an improvement of about two months in progression-free survival (PFS) in both trials, and in the ECOG4599 trial, an improvement in overall survival (OS) also. Afterwards, other antiangiogenic agents, including sunitinib, sorafenib, and vandetanib have been unsuccessfully tested in first and successive lines. Recently, two new antiangiogenic agents (ramucirumab and nintedanib) produced a significant survival benefit in second-line setting. In the REVEL study, ramucirumab plus docetaxel prolonged the median OS of patients with any histology NSCLC when compared with docetaxel alone (10.4 versus 9.1 months, hazard ratio (HR) 0.857, p = 0.0235). In the LUME-Lung 1 study, nintedanib plus docetaxel prolonged the median PFS of patients with any tumor histology (p = 0.0019), and improved OS (12.6 versus 10.3 months) in patients with adenocarcinoma. As a result, it became a new option for the second-line treatment of patients with advanced NSCLC and adenocarcinoma histology. Identifying predictive biomarkers to optimize the benefit of antiangiogenic drugs remains an ongoing challenge.https://www.mdpi.com/1422-0067/18/10/2021angiogenesisvascular endothelial growth factor (VEGF)bevacizumabnintedanibramucirumabVEGF trap |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anna Manzo Agnese Montanino Guido Carillio Raffaele Costanzo Claudia Sandomenico Nicola Normanno Maria Carmela Piccirillo Gennaro Daniele Francesco Perrone Gaetano Rocco Alessandro Morabito |
spellingShingle |
Anna Manzo Agnese Montanino Guido Carillio Raffaele Costanzo Claudia Sandomenico Nicola Normanno Maria Carmela Piccirillo Gennaro Daniele Francesco Perrone Gaetano Rocco Alessandro Morabito Angiogenesis Inhibitors in NSCLC International Journal of Molecular Sciences angiogenesis vascular endothelial growth factor (VEGF) bevacizumab nintedanib ramucirumab VEGF trap |
author_facet |
Anna Manzo Agnese Montanino Guido Carillio Raffaele Costanzo Claudia Sandomenico Nicola Normanno Maria Carmela Piccirillo Gennaro Daniele Francesco Perrone Gaetano Rocco Alessandro Morabito |
author_sort |
Anna Manzo |
title |
Angiogenesis Inhibitors in NSCLC |
title_short |
Angiogenesis Inhibitors in NSCLC |
title_full |
Angiogenesis Inhibitors in NSCLC |
title_fullStr |
Angiogenesis Inhibitors in NSCLC |
title_full_unstemmed |
Angiogenesis Inhibitors in NSCLC |
title_sort |
angiogenesis inhibitors in nsclc |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2017-09-01 |
description |
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy; however, it was limited to patients with non-squamous histology and first-line setting. Approval was based on the results of two phase III trials (ECOG4599 and AVAIL) that demonstrated an improvement of about two months in progression-free survival (PFS) in both trials, and in the ECOG4599 trial, an improvement in overall survival (OS) also. Afterwards, other antiangiogenic agents, including sunitinib, sorafenib, and vandetanib have been unsuccessfully tested in first and successive lines. Recently, two new antiangiogenic agents (ramucirumab and nintedanib) produced a significant survival benefit in second-line setting. In the REVEL study, ramucirumab plus docetaxel prolonged the median OS of patients with any histology NSCLC when compared with docetaxel alone (10.4 versus 9.1 months, hazard ratio (HR) 0.857, p = 0.0235). In the LUME-Lung 1 study, nintedanib plus docetaxel prolonged the median PFS of patients with any tumor histology (p = 0.0019), and improved OS (12.6 versus 10.3 months) in patients with adenocarcinoma. As a result, it became a new option for the second-line treatment of patients with advanced NSCLC and adenocarcinoma histology. Identifying predictive biomarkers to optimize the benefit of antiangiogenic drugs remains an ongoing challenge. |
topic |
angiogenesis vascular endothelial growth factor (VEGF) bevacizumab nintedanib ramucirumab VEGF trap |
url |
https://www.mdpi.com/1422-0067/18/10/2021 |
work_keys_str_mv |
AT annamanzo angiogenesisinhibitorsinnsclc AT agnesemontanino angiogenesisinhibitorsinnsclc AT guidocarillio angiogenesisinhibitorsinnsclc AT raffaelecostanzo angiogenesisinhibitorsinnsclc AT claudiasandomenico angiogenesisinhibitorsinnsclc AT nicolanormanno angiogenesisinhibitorsinnsclc AT mariacarmelapiccirillo angiogenesisinhibitorsinnsclc AT gennarodaniele angiogenesisinhibitorsinnsclc AT francescoperrone angiogenesisinhibitorsinnsclc AT gaetanorocco angiogenesisinhibitorsinnsclc AT alessandromorabito angiogenesisinhibitorsinnsclc |
_version_ |
1725934040726372352 |